Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present KemPharm, Inc. (NASDAQ: KMPH).

Full DD Report for KMPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: KMPH)

Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
KemPharm to Present at Two Healthcare Investor Conferences During September 2018
CORALVILLE, Iowa, Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at t...
Source: GlobeNewswire
Date: September, 05 2018 07:30
FDA rejects Sunovion's dasotraline for ADHD
Privately-held Sunovion Pharmaceuticals has received a CRL from the FDA in response to its marketing application seeking approval for dasotraline, a dual-acting dopamine and norepinephrine reuptake inhibitor, for the treatment of attention deficit hyperactivity disorder (ADHD). More ne...
Source: SeekingAlpha
Date: August, 31 2018 09:47
FDA updates on multifaceted plan to combat opioid crisis
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:44
FDA clamps down on opioid-peddling websites
The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc...
Source: SeekingAlpha
Date: August, 28 2018 10:57
FDA awards contract to develop guidelines for opioid prescribing
The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND...
Source: SeekingAlpha
Date: August, 22 2018 11:16
White House proposing cuts in opioid production
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &...
Source: SeekingAlpha
Date: August, 16 2018 15:24
KemPharm's (KMPH) CEO Travis Mickle on Q2 2018 Results - Earnings Call Transcript
KemPharm (KMPH) Q2 2018 Earnings Conference Call August 9, 2018 4:30 PM ET Executives Dan Cohen – Executive Vice President Travis Mickle – President and Chief Executive Officer LaDuane Clifton – Chief Financial Officer Analysts Randall Stanicky –...
Source: SeekingAlpha
Date: August, 10 2018 17:48
KemPharm (KMPH) Presents at Canaccord Genuity 38th Annual Growth Conference - Slideshow
The following slide deck was published by KemPharm in conjunction with this Read more ...
Source: SeekingAlpha
Date: August, 10 2018 15:33
KemPharm Reports Q2 Earnings - Financials Are Secondary To Binary Events
When quarterly reports come out, investors are usually geared to looking at the financials, assessing a profit or loss and seeing if a company is performing more strongly than it was a year or a quarter ago. These are all important factors to consider in an investment, but with the KemPharm Q...
Source: SeekingAlpha
Date: August, 09 2018 23:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-122.782.73012.892.7007168,445
2018-12-112.782.792.822.7115127,987
2018-12-102.812.752.892.65225,307
2018-12-072.972.78993.002.5801355,096
2018-12-062.632.892.942.50997,553

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1228,59271,93839.7453Short
2018-12-1116,05535,64245.0452Short
2018-12-1027,74599,82027.7950Cover
2018-12-0770,524177,31139.7742Short
2018-12-06198,476439,48545.1610Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KMPH.


About KemPharm, Inc. (NASDAQ: KMPH)

Logo for KemPharm, Inc. (NASDAQ: KMPH)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $89,118,603 - 05/11/2018
  • Issue and Outstanding: 15,104,848 - 03/28/2018

 


Recent Filings from (NASDAQ: KMPH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: KMPH)

Daily Technical Chart for (NASDAQ: KMPH)


Stay tuned for daily updates and more on (NASDAQ: KMPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KMPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KMPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KMPH and does not buy, sell, or trade any shares of KMPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/